Research Article
BibTex RIS Cite

Vaccination Against SARS-CoV-2 and Mortality in Hemodialysis Patients: Three is Good

Year 2023, Volume: 6 Issue: 3, 398 - 403, 01.07.2023

Demet Yavuz , Düriye Sıla Karagöz Özen , Eşe Başbulut , Melek Bilgin , Mehmet Derya Demirag

https://doi.org/10.19127/bshealthscience.1274888

Abstract

This study has investigated the vaccination rates against SARS-CoV-2 infection, antibody response to vaccine types, and factors affecting mortality in maintenance hemodialysis patients.98 of 143 patients undergoing hemodialysis in our clinic had 3 doses of BNT162b2 (Pfizer-BioNTechh) or CoronaVac (Sinovac Life Sciences) vaccine. Of these 98 patients, blood samples were obtained from 52 patients who agreed to obtain serum samples before and after vaccination. The serum samples were analyzed using the Abbott SARS-CoV-2 immunoassay designed to detect IgG antibodies against the receptor-binding domain of the S1 subunit of the spike protein of SARS-CoV-2. The rate of vaccination with at least one dose of vaccine was 85.3%, and the frequency of SARS-CoV-2 infection was 58.7%. The patients whose antibody titer was obtained after the third dose of vaccine (n=52) were divided into two groups according to the last vaccine type, as BioNTechh group of 16 patients and the Sinovac group of 36 patients. Considering all 52 patients with 3 doses of vaccine, the median antibody level was 397.3 (min-max) (4.5-40000) before the third vaccine dose, while 1325.3 (min-max) (10.5-40000) after the third vaccine dose (P<0.001). In patients with the last vaccine dose of Sinovac (n=36), the median antibody titer was 168.2 (min-max) (4.5-40000) before the third vaccine dose, while 851.7 (min-max) (55.2-40.000) after the third vaccine dose (P<0.01). In patients with the last vaccine dose of BioNTechh, the median antibody titer was 2738.6 (min-max) (9.4-37723.4) before the third vaccine dose, while 37575.8 (min-max) (10.5-40000) after the third vaccine dose (P=0.002). The frequency of SARS-CoV-2 infection (P=0.001) and SARS-CoV-2 infection-related mortality rates were significantly lower in vaccinated patients than in unvaccinated patients (P<0.001). SARS-CoV-2 vaccine doses elicited a high seropositive response in patients receiving maintenance dialysis. Those who received the last (3rd) dose of vaccine with BNT162b2 had higher antibody levels than those with CoronaVac/Sinovac. In addition, regardless of the vaccine type, being vaccinated with any of them decreased the incidence of SARS-CoV-2 infection and the mortality rate.

Keywords

COVID-19 vaccination SARS-CoV-2 Maintenance hemodialysis Mortality

References

  • Asan A, Demirhan H, Sorkun HÇ, Özkan S, Aydın M, Akın D. 2017. Factors affecting responsiveness to hepatitis B immunization in dialysis patients. Int Urol Nephrol, 49(10): 1845-1850.
  • Bayram A, Demirbakan H, Günel Karadeniz P, Erdoğan M, Koçer I. 2021. Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers. J Med Virol, 93(9): 5560-5567.
  • Bensouna I, Caudwell V, Kubab S, Acquaviva S, Pardon A, Vittoz N, et al.2022. SARS-CoV-2 Antibody response after a third dose of the BNT162b2 vaccine in patients receiving maintenance hemodialysis or peritoneal dialysis. Am J Kidney Dis, 79(2): 185-192.
  • Caillard S, Thaunat O, Benotmane I, Masset C, Blancho G. 2022. Antibody response to a fourth messenger RNA COVID-19 vaccine dose in kidney transplant recipients: A case series. Ann Intern Med, 175(3): 455-456
  • Cao Y, Yisimayi A, Bai Y, Huang W, Li X, Zhang Z. 2021. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. Cell Res, 31(7): 732-741.
  • Dekervel M, Henry N, Torreggiani M, Pouteau LM, Imiela JP, Mellaza C. 2021. Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis. Clin Kidney J, 14(11): 2349-2355.
  • Ducloux D, Colladant M, Chabannes M, Yannaraki M, Courivaud C. 2021. Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis. Kidney Int, 100(3): 702-704.
  • Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR. 2021. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine, 39(32): 4423-4428.
  • Espi M, Charmetant X, Barba T, Koppe L, Pelletier C, Kalbacher E. 2021. The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis. Kidney Int, 100(4): 928-936.
  • Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A. 2020. Clinical characteristics of Covid-19 in New York City. N Engl J Med, 382(24): 2372-2374.
  • Grupper A, Sharon N, Finn T, Cohen R, Israel M, Agbaria A. 2021. Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol, 16(7): 1037-1042.
  • Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. 2021. Effect of vaccination on household transmission of SARS-CoV-2 in England .N Engl J Med, 385(8): 759-760.
  • Hsu CM, Weiner DE, Manley HJ, Aweh GN, Ladik V, Frament J. 2022. Seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients over 6 months. Clin J Am Soc Nephrol, 17(3): 403-413.
  • Keskin AU, Bolukcu S, Ciragil P, Topkaya AE. 2022. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. J Med Virol, 94(1): 39-41.
  • Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY. 2020. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect, 53(3): 404-412.
  • Longlune N, Nogier MB, Miedougé M, Gabilan C, Cartou C, Seigneuric B. 2021. High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. Nephrol Dial Transplant, 36(9): 1704-1709.
  • Myers LC, Parodi SM, Escobar GJ, Liu VX. 2020. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. JAMA, 323(21): 2195-2198.
  • Önder H. 2018. Nonparametric statistical methods used in biological experiments. BSJ Eng Sci, 1(1): 1-6.
  • Önder H. 2020. Short-term forecasts of the COVID-19 epidemic in Turkey: March 16–28, 2020. BSJ Health Sci, 3(2): 27-30.
  • Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J. 2020. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA, 323(24): 2493-2502.
  • Shimada N, Shimada H, Itaya Y, Tomino Y. 2021. Novel coronavirus disease in patients with end-stage kidney disease. Ther Apher Dial, 25(5): 544-550
  • Speer C, Göth D, Benning L, Buylaert M, Schaier M, Grenz J. 2021. Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2. Clin J Am Soc Nephrol, 16(7): 1073-1082.
  • URL1: https://covid19asi.saglik.gov.tr/EN-80229/turkeys-national-immunization-program.htlm. (accessed date: December 6, 2021).
  • Yavuz E, Günal Ö, Başbulut E, Şen A. 2022. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine. J Med Virol, 94(8): 3768-3775. DOI: 10.1002/jmv.27794.
  • Yen CC, Lin SY, Chen SC, Chiu YW, Chang JM, Hwang SJ. 2021. COVID-19 vaccines in patients with maintenance hemodialysis. J Pers Med, 11(8): 789.

Vaccination Against SARS-CoV-2 and Mortality in Hemodialysis Patients: Three is Good

Year 2023, Volume: 6 Issue: 3, 398 - 403, 01.07.2023

Demet Yavuz , Düriye Sıla Karagöz Özen , Eşe Başbulut , Melek Bilgin , Mehmet Derya Demirag

https://doi.org/10.19127/bshealthscience.1274888

Abstract

This study has investigated the vaccination rates against SARS-CoV-2 infection, antibody response to vaccine types, and factors affecting mortality in maintenance hemodialysis patients.98 of 143 patients undergoing hemodialysis in our clinic had 3 doses of BNT162b2 (Pfizer-BioNTechh) or CoronaVac (Sinovac Life Sciences) vaccine. Of these 98 patients, blood samples were obtained from 52 patients who agreed to obtain serum samples before and after vaccination. The serum samples were analyzed using the Abbott SARS-CoV-2 immunoassay designed to detect IgG antibodies against the receptor-binding domain of the S1 subunit of the spike protein of SARS-CoV-2. The rate of vaccination with at least one dose of vaccine was 85.3%, and the frequency of SARS-CoV-2 infection was 58.7%. The patients whose antibody titer was obtained after the third dose of vaccine (n=52) were divided into two groups according to the last vaccine type, as BioNTechh group of 16 patients and the Sinovac group of 36 patients. Considering all 52 patients with 3 doses of vaccine, the median antibody level was 397.3 (min-max) (4.5-40000) before the third vaccine dose, while 1325.3 (min-max) (10.5-40000) after the third vaccine dose (P<0.001). In patients with the last vaccine dose of Sinovac (n=36), the median antibody titer was 168.2 (min-max) (4.5-40000) before the third vaccine dose, while 851.7 (min-max) (55.2-40.000) after the third vaccine dose (P<0.01). In patients with the last vaccine dose of BioNTechh, the median antibody titer was 2738.6 (min-max) (9.4-37723.4) before the third vaccine dose, while 37575.8 (min-max) (10.5-40000) after the third vaccine dose (P=0.002). The frequency of SARS-CoV-2 infection (P=0.001) and SARS-CoV-2 infection-related mortality rates were significantly lower in vaccinated patients than in unvaccinated patients (P<0.001). SARS-CoV-2 vaccine doses elicited a high seropositive response in patients receiving maintenance dialysis. Those who received the last (3rd) dose of vaccine with BNT162b2 had higher antibody levels than those with CoronaVac/Sinovac. In addition, regardless of the vaccine type, being vaccinated with any of them decreased the incidence of SARS-CoV-2 infection and the mortality rate.

Keywords

COVID-19 vaccination SARS-CoV-2 Maintenance hemodialysis Mortality

References

  • Asan A, Demirhan H, Sorkun HÇ, Özkan S, Aydın M, Akın D. 2017. Factors affecting responsiveness to hepatitis B immunization in dialysis patients. Int Urol Nephrol, 49(10): 1845-1850.
  • Bayram A, Demirbakan H, Günel Karadeniz P, Erdoğan M, Koçer I. 2021. Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers. J Med Virol, 93(9): 5560-5567.
  • Bensouna I, Caudwell V, Kubab S, Acquaviva S, Pardon A, Vittoz N, et al.2022. SARS-CoV-2 Antibody response after a third dose of the BNT162b2 vaccine in patients receiving maintenance hemodialysis or peritoneal dialysis. Am J Kidney Dis, 79(2): 185-192.
  • Caillard S, Thaunat O, Benotmane I, Masset C, Blancho G. 2022. Antibody response to a fourth messenger RNA COVID-19 vaccine dose in kidney transplant recipients: A case series. Ann Intern Med, 175(3): 455-456
  • Cao Y, Yisimayi A, Bai Y, Huang W, Li X, Zhang Z. 2021. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. Cell Res, 31(7): 732-741.
  • Dekervel M, Henry N, Torreggiani M, Pouteau LM, Imiela JP, Mellaza C. 2021. Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis. Clin Kidney J, 14(11): 2349-2355.
  • Ducloux D, Colladant M, Chabannes M, Yannaraki M, Courivaud C. 2021. Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis. Kidney Int, 100(3): 702-704.
  • Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR. 2021. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine, 39(32): 4423-4428.
  • Espi M, Charmetant X, Barba T, Koppe L, Pelletier C, Kalbacher E. 2021. The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis. Kidney Int, 100(4): 928-936.
  • Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A. 2020. Clinical characteristics of Covid-19 in New York City. N Engl J Med, 382(24): 2372-2374.
  • Grupper A, Sharon N, Finn T, Cohen R, Israel M, Agbaria A. 2021. Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol, 16(7): 1037-1042.
  • Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. 2021. Effect of vaccination on household transmission of SARS-CoV-2 in England .N Engl J Med, 385(8): 759-760.
  • Hsu CM, Weiner DE, Manley HJ, Aweh GN, Ladik V, Frament J. 2022. Seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients over 6 months. Clin J Am Soc Nephrol, 17(3): 403-413.
  • Keskin AU, Bolukcu S, Ciragil P, Topkaya AE. 2022. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. J Med Virol, 94(1): 39-41.
  • Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY. 2020. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect, 53(3): 404-412.
  • Longlune N, Nogier MB, Miedougé M, Gabilan C, Cartou C, Seigneuric B. 2021. High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. Nephrol Dial Transplant, 36(9): 1704-1709.
  • Myers LC, Parodi SM, Escobar GJ, Liu VX. 2020. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. JAMA, 323(21): 2195-2198.
  • Önder H. 2018. Nonparametric statistical methods used in biological experiments. BSJ Eng Sci, 1(1): 1-6.
  • Önder H. 2020. Short-term forecasts of the COVID-19 epidemic in Turkey: March 16–28, 2020. BSJ Health Sci, 3(2): 27-30.
  • Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J. 2020. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA, 323(24): 2493-2502.
  • Shimada N, Shimada H, Itaya Y, Tomino Y. 2021. Novel coronavirus disease in patients with end-stage kidney disease. Ther Apher Dial, 25(5): 544-550
  • Speer C, Göth D, Benning L, Buylaert M, Schaier M, Grenz J. 2021. Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2. Clin J Am Soc Nephrol, 16(7): 1073-1082.
  • URL1: https://covid19asi.saglik.gov.tr/EN-80229/turkeys-national-immunization-program.htlm. (accessed date: December 6, 2021).
  • Yavuz E, Günal Ö, Başbulut E, Şen A. 2022. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine. J Med Virol, 94(8): 3768-3775. DOI: 10.1002/jmv.27794.
  • Yen CC, Lin SY, Chen SC, Chiu YW, Chang JM, Hwang SJ. 2021. COVID-19 vaccines in patients with maintenance hemodialysis. J Pers Med, 11(8): 789.
There are 25 citations in total.

Details

Primary Language English
Subjects ​Internal Diseases
Journal Section Research Article
Authors

Demet Yavuz 0000-0002-4082-6320

Düriye Sıla Karagöz Özen 0000-0001-7852-2114

Eşe Başbulut 0000-0001-8235-9524

Melek Bilgin 0000-0003-0025-8717

Mehmet Derya Demirag 0000-0001-5667-1805

Early Pub Date June 20, 2023
Publication Date July 1, 2023
Submission Date March 31, 2023
Acceptance Date May 17, 2023
Published in Issue Year 2023 Volume: 6 Issue: 3

Cite

APA Yavuz, D., Karagöz Özen, D. S., Başbulut, E., Bilgin, M., et al. (2023). Vaccination Against SARS-CoV-2 and Mortality in Hemodialysis Patients: Three is Good. Black Sea Journal of Health Science, 6(3), 398-403. https://doi.org/10.19127/bshealthscience.1274888
AMA Yavuz D, Karagöz Özen DS, Başbulut E, Bilgin M, Demirag MD. Vaccination Against SARS-CoV-2 and Mortality in Hemodialysis Patients: Three is Good. BSJ Health Sci. July 2023;6(3):398-403. doi:10.19127/bshealthscience.1274888
Chicago Yavuz, Demet, Düriye Sıla Karagöz Özen, Eşe Başbulut, Melek Bilgin, and Mehmet Derya Demirag. “Vaccination Against SARS-CoV-2 and Mortality in Hemodialysis Patients: Three Is Good”. Black Sea Journal of Health Science 6, no. 3 (July 2023): 398-403. https://doi.org/10.19127/bshealthscience.1274888.
EndNote Yavuz D, Karagöz Özen DS, Başbulut E, Bilgin M, Demirag MD (July 1, 2023) Vaccination Against SARS-CoV-2 and Mortality in Hemodialysis Patients: Three is Good. Black Sea Journal of Health Science 6 3 398–403.
IEEE D. Yavuz, D. S. Karagöz Özen, E. Başbulut, M. Bilgin, and M. D. Demirag, “Vaccination Against SARS-CoV-2 and Mortality in Hemodialysis Patients: Three is Good”, BSJ Health Sci., vol. 6, no. 3, pp. 398–403, 2023, doi: 10.19127/bshealthscience.1274888.
ISNAD Yavuz, Demet et al. “Vaccination Against SARS-CoV-2 and Mortality in Hemodialysis Patients: Three Is Good”. Black Sea Journal of Health Science 6/3 (July 2023), 398-403. https://doi.org/10.19127/bshealthscience.1274888.
JAMA Yavuz D, Karagöz Özen DS, Başbulut E, Bilgin M, Demirag MD. Vaccination Against SARS-CoV-2 and Mortality in Hemodialysis Patients: Three is Good. BSJ Health Sci. 2023;6:398–403.
MLA Yavuz, Demet et al. “Vaccination Against SARS-CoV-2 and Mortality in Hemodialysis Patients: Three Is Good”. Black Sea Journal of Health Science, vol. 6, no. 3, 2023, pp. 398-03, doi:10.19127/bshealthscience.1274888.
Vancouver Yavuz D, Karagöz Özen DS, Başbulut E, Bilgin M, Demirag MD. Vaccination Against SARS-CoV-2 and Mortality in Hemodialysis Patients: Three is Good. BSJ Health Sci. 2023;6(3):398-403.
 Download Cover Image